schliessen

Filtern

 

Bibliotheken

Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.

BACKGROUNDThe current study was performed to evaluate the efficacy and toxicity of a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel as front-line chemotherapy for patients with carcinoma of an unknown primary site. METHODSPatients were to receive intravenous gemcitabine... Full description

Journal Title: Cancer March 15, 2004, Vol.100(6), pp.1257-1261
Main Author: Pouessel, Damien
Other Authors: Culine, Stéphane , Becht, Catherine , Ychou, Marc , Romieu, Gilles , Fabbro, Michel , Cupissol, Didier , Pinguet, Frédéric
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-543X
Link: http://search.proquest.com/docview/71721451/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest71721451
title: Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
format: Article
creator:
  • Pouessel, Damien
  • Culine, Stéphane
  • Becht, Catherine
  • Ychou, Marc
  • Romieu, Gilles
  • Fabbro, Michel
  • Cupissol, Didier
  • Pinguet, Frédéric
subjects:
  • Adult–Adverse Effects
  • Antineoplastic Agents–Therapeutic Use
  • Antineoplastic Combined Chemotherapy Protocols–Adverse Effects
  • Carcinoma–Therapeutic Use
  • Deoxycytidine–Drug Therapy
  • Humans–Secondary
  • Neoplasms, Unknown Primary–Administration & Dosage
  • Survival Analysis–Adverse Effects
  • Taxoids–Analogs & Derivatives
  • Treatment Outcome–Therapeutic Use
  • Treatment Outcome–Drug Therapy
  • Treatment Outcome–Administration & Dosage
  • Treatment Outcome–Adverse Effects
  • Treatment Outcome–Therapeutic Use
  • Abridged
  • Antineoplastic Agents
  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • Gemcitabine
ispartof: Cancer, March 15, 2004, Vol.100(6), pp.1257-1261
description: BACKGROUNDThe current study was performed to evaluate the efficacy and toxicity of a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel as front-line chemotherapy for patients with carcinoma of an unknown primary site. METHODSPatients were to receive intravenous gemcitabine at a dose of 1000 mg/m2 over 30 minutes on Days 1 and 8 and docetaxel at a dose of 75 mg/m2 over 1 hour on Day 8 in an outpatient setting. The schedule was repeated every 3 weeks for a maximum of 6 cycles. RESULTSThirty-five patients were assessable for response and survival. One complete and 13 partial responses were observed. The overall response rate was 40% (95% confidence interval, 28-52%). The median time to disease progression was 2 months (range, 1-4 months). The median overall survival time was 10 months (range, 0-32 months). Toxicity was reported to be manageable. CONCLUSIONSThe combination of gemcitabine and docetaxel was found to be active in patients with carcinomas of an unknown primary site. However, the overall outcome of these patients remains poor and novel treatment approaches are required.
language: eng
source:
identifier: ISSN: 0008-543X
fulltext: fulltext
issn:
  • 0008543X
  • 0008-543X
url: Link


@attributes
ID1735242489
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid71721451
sourceidproquest
recordidTN_proquest71721451
sourcesystemOther
pqid71721451
galeid133724165
display
typearticle
titleGemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
creatorPouessel, Damien ; Culine, Stéphane ; Becht, Catherine ; Ychou, Marc ; Romieu, Gilles ; Fabbro, Michel ; Cupissol, Didier ; Pinguet, Frédéric
contributorPouessel, Damien (correspondence author) ; Pouessel, Damien (record owner)
ispartofCancer, March 15, 2004, Vol.100(6), pp.1257-1261
identifierISSN: 0008-543X
subjectAdult–Adverse Effects ; Antineoplastic Agents–Therapeutic Use ; Antineoplastic Combined Chemotherapy Protocols–Adverse Effects ; Carcinoma–Therapeutic Use ; Deoxycytidine–Drug Therapy ; Humans–Secondary ; Neoplasms, Unknown Primary–Administration & Dosage ; Survival Analysis–Adverse Effects ; Taxoids–Analogs & Derivatives ; Treatment Outcome–Therapeutic Use ; Treatment Outcome–Drug Therapy ; Treatment Outcome–Administration & Dosage ; Treatment Outcome–Adverse Effects ; Treatment Outcome–Therapeutic Use ; Abridged ; Antineoplastic Agents ; Taxoids ; Deoxycytidine ; Docetaxel ; Gemcitabine
descriptionBACKGROUNDThe current study was performed to evaluate the efficacy and toxicity of a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel as front-line chemotherapy for patients with carcinoma of an unknown primary site. METHODSPatients were to receive intravenous gemcitabine at a dose of 1000 mg/m2 over 30 minutes on Days 1 and 8 and docetaxel at a dose of 75 mg/m2 over 1 hour on Day 8 in an outpatient setting. The schedule was repeated every 3 weeks for a maximum of 6 cycles. RESULTSThirty-five patients were assessable for response and survival. One complete and 13 partial responses were observed. The overall response rate was 40% (95% confidence interval, 28-52%). The median time to disease progression was 2 months (range, 1-4 months). The median overall survival time was 10 months (range, 0-32 months). Toxicity was reported to be manageable. CONCLUSIONSThe combination of gemcitabine and docetaxel was found to be active in patients with carcinomas of an unknown primary site. However, the overall outcome of these patients remains poor and novel treatment approaches are required.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/71721451/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Pouessel, Damien
1Culine, Stéphane
2Becht, Catherine
3Ychou, Marc
4Romieu, Gilles
5Fabbro, Michel
6Cupissol, Didier
7Pinguet, Frédéric
titleGemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
descriptionBACKGROUNDThe current study was performed to evaluate the efficacy and toxicity of a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel as front-line chemotherapy for patients with carcinoma of an unknown primary site. METHODSPatients were to receive intravenous gemcitabine at a dose of 1000 mg/m2 over 30 minutes on Days 1 and 8 and docetaxel at a dose of 75 mg/m2 over 1 hour on Day 8 in an outpatient setting. The schedule was repeated every 3 weeks for a maximum of 6 cycles. RESULTSThirty-five patients were assessable for response and survival. One complete and 13 partial responses were observed. The overall response rate was 40% (95% confidence interval, 28-52%). The median time to disease progression was 2 months (range, 1-4 months). The median overall survival time was 10 months (range, 0-32 months). Toxicity was reported to be manageable. CONCLUSIONSThe combination of gemcitabine and docetaxel was found to be active in patients with carcinomas of an unknown primary site. However, the overall outcome of these patients remains poor and novel treatment approaches are required.
subject
0Adult–Adverse Effects
1Antineoplastic Agents–Therapeutic Use
2Antineoplastic Combined Chemotherapy Protocols–Adverse Effects
3Carcinoma–Therapeutic Use
4Deoxycytidine–Drug Therapy
5Humans–Secondary
6Neoplasms, Unknown Primary–Administration & Dosage
7Survival Analysis–Adverse Effects
8Taxoids–Analogs & Derivatives
9Treatment Outcome–Therapeutic Use
10Treatment Outcome–Drug Therapy
11Treatment Outcome–Administration & Dosage
12Treatment Outcome–Adverse Effects
13Abridged
14Antineoplastic Agents
15Taxoids
16Deoxycytidine
17Docetaxel
18Gemcitabine
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Environmental Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Agricultural & Environmental Science Database
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest71721451
issn
00008543X
10008-543X
rsrctypearticle
creationdate2004
addtitleCancer
searchscope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
scope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
lsr43
01007489false
11007527false
21007944false
310000004false
410000006false
510000038false
610000043false
710000050false
810000120false
910000159false
1010000198false
1110000200false
1210000209false
1310000217false
1410000234false
1510000238false
1610000253false
1710000260false
1810000270false
1910000271false
2010000302false
contributorPouessel, Damien
startdate20040315
enddate20040315
citationpf 1257 pt 1261 vol 100 issue 6
lsr30VSR-Enriched:[doi, galeid, pqid, eissn]
sort
titleGemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
authorPouessel, Damien ; Culine, Stéphane ; Becht, Catherine ; Ychou, Marc ; Romieu, Gilles ; Fabbro, Michel ; Cupissol, Didier ; Pinguet, Frédéric
creationdate20040315
lso0120040315
facets
frbrgroupid832710570490649932
frbrtype5
newrecords20181218
languageeng
creationdate2004
topic
0Adult–Adverse Effects
1Antineoplastic Agents–Therapeutic Use
2Antineoplastic Combined Chemotherapy Protocols–Adverse Effects
3Carcinoma–Therapeutic Use
4Deoxycytidine–Drug Therapy
5Humans–Secondary
6Neoplasms, Unknown Primary–Administration & Dosage
7Survival Analysis–Adverse Effects
8Taxoids–Analogs & Derivatives
9Treatment Outcome–Therapeutic Use
10Treatment Outcome–Drug Therapy
11Treatment Outcome–Administration & Dosage
12Treatment Outcome–Adverse Effects
13Abridged
14Antineoplastic Agents
15Taxoids
16Deoxycytidine
17Docetaxel
18Gemcitabine
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Environmental Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Agricultural & Environmental Science Database
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Pouessel, Damien
1Culine, Stéphane
2Becht, Catherine
3Ychou, Marc
4Romieu, Gilles
5Fabbro, Michel
6Cupissol, Didier
7Pinguet, Frédéric
jtitleCancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Pouessel
1Culine
2Becht
3Ychou
4Romieu
5Fabbro
6Cupissol
7Pinguet
aufirst
0Damien
1Stéphane
2Catherine
3Marc
4Gilles
5Michel
6Didier
7Frédéric
au
0Pouessel, Damien
1Culine, Stéphane
2Becht, Catherine
3Ychou, Marc
4Romieu, Gilles
5Fabbro, Michel
6Cupissol, Didier
7Pinguet, Frédéric
addauPouessel, Damien
atitleGemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
jtitleCancer
risdate20040315
volume100
issue6
spage1257
epage1261
pages1257-1261
issn0008-543X
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDThe current study was performed to evaluate the efficacy and toxicity of a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel as front-line chemotherapy for patients with carcinoma of an unknown primary site. METHODSPatients were to receive intravenous gemcitabine at a dose of 1000 mg/m2 over 30 minutes on Days 1 and 8 and docetaxel at a dose of 75 mg/m2 over 1 hour on Day 8 in an outpatient setting. The schedule was repeated every 3 weeks for a maximum of 6 cycles. RESULTSThirty-five patients were assessable for response and survival. One complete and 13 partial responses were observed. The overall response rate was 40% (95% confidence interval, 28-52%). The median time to disease progression was 2 months (range, 1-4 months). The median overall survival time was 10 months (range, 0-32 months). Toxicity was reported to be manageable. CONCLUSIONSThe combination of gemcitabine and docetaxel was found to be active in patients with carcinomas of an unknown primary site. However, the overall outcome of these patients remains poor and novel treatment approaches are required.
urlhttp://search.proquest.com/docview/71721451/
doi10.1002/cncr.20100
eissn10970142
date2004-03-15